SCHEMBL30756440

SCHEMBL30756440

C=Cc1cnc(NC(C)=O)cc1NC(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ GSK3B P49841 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ AAK1 Q2M2I8 2/20 0.38
▸ PTK2 Q05397 1/20 0.35
▸ CYP17A1 P05093 1/20 0.35
▸ SYK P43405 1/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ CCNB2 O95067 1/20 0.34
▸ CCNE2 O96020 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ CDK4 P11802 1/20 0.34
▸ CCNB1 P14635 1/20 0.34
▸ CCND1 P24385 1/20 0.34
▸ CCNE1 P24864 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ CCNB3 Q8WWL7 1/20 0.34
▸ JAK1 P23458 2/20 0.34
▸ TYK2 P29597 2/20 0.34
▸ METAP1 P53582 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30756492 0.83 L3MBTL1 (0.42) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL30755633 0.83 AAK1 (0.44) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL30756196 0.82 L3MBTL1 (0.40) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL30755583 0.82 L3MBTL1 (0.41) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL18414738 0.82 CYP17A1 (0.43) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL30755571 0.81 L3MBTL1 (0.41) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL30756228 0.81 AAK1 (0.42) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL30756302 0.81 L3MBTL1 (0.41) L3MBTL1GSK3BDYRK1AAAK1PTK2
SCHEMBL30756282 0.81 L3MBTL1 (0.41) L3MBTL1GSK3BDYRK1AAAK1TYK2
SCHEMBL30756067 0.80 L3MBTL1 (0.40) L3MBTL1GSK3BDYRK1AAAK1PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-29 — — US disclosed
EP-4554938-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 — — EP disclosed
CN-119894879-A Tyrosine kinase 2 inhibitors and uses thereof 渤健马萨诸塞州股份有限公司 2025-04-25 — — CN disclosed
WO-2024015497-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028365-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF TYK2, ERBB2, ROS1 L3MBTL1 3018/4885GSK3B 192/4885DYRK1A 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback